2021 AACC Annual Scientific Meeting to Require Both Proof of COVID-19 Vaccination and Negative Test from All In-Person Attendees
|
By LabMedica International staff writers Posted on 31 Aug 2021 |

Illustration
The 2021 American Association for Clinical Chemistry (AACC; Washington, DC, USA) Annual Scientific Meeting & Clinical Lab Expo will be a live event with new location and dates, backed by plans to make the meeting a safe and productive one amidst the flare up in the COVID-19 pandemic.
This year's AACC Annual Scientific Meeting, held in partnership with the Canadian Society of Clinical Chemists, has moved from Anaheim to Atlanta due to stringent COVID-19 lockdown requirements in California, and the meeting dates have also moved by one week to September 26-30. In his latest email, AACC 2021 President Dr. Stephen Master, PhD, had outlined the extensive health and safety planning to make this year’s AACC Annual Scientific Meeting and Clinical Lab Expo in Atlanta a safe and productive in-person meeting. In order to ensure the safety of all attendees, the email clearly stated that unvaccinated people would not be permitted into the conference and expo campus without a current, negative SARS-CoV-2 antigen test or verified proof of vaccination.
As per its latest update, AACC now requires all meeting participants to be vaccinated, and for all meeting participants to have received a negative PCR or antigen COVID-19 test within 72 hours of arriving at the convention center. Proof of COVID-19 vaccination AND proof of a negative PCR or antigen coronavirus test will be required for in-person attendees of the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo. Individuals who are unable to provide both of these things will not be permitted to enter the meeting and antibody test results will not be accepted.
Additionally, mask policies will be in place and strictly enforced. All persons within the AACC meeting campus must wear a face mask covering their nose and mouth at all times they are indoors. Moreover, detailed meeting logistics and design have been laid down to prevent crowding and disperse crowding at the event, and additional measures may be taken if required. Signage will be used to encourage social distancing, plexiglass separations will be placed at points of sale, and educational session times will be staggered to reduce the number of attendees in common areas.
“Our plans to hold a safe and productive in-person meeting in Atlanta have not changed,” wrote Dr. Stephen Master. “The meeting is on, and it will be safe.”
“I encourage you to check out the conference program if you haven’t already. And I look forward to seeing many of you in Atlanta next month,” he added.
Related Links:
American Association for Clinical Chemistry
This year's AACC Annual Scientific Meeting, held in partnership with the Canadian Society of Clinical Chemists, has moved from Anaheim to Atlanta due to stringent COVID-19 lockdown requirements in California, and the meeting dates have also moved by one week to September 26-30. In his latest email, AACC 2021 President Dr. Stephen Master, PhD, had outlined the extensive health and safety planning to make this year’s AACC Annual Scientific Meeting and Clinical Lab Expo in Atlanta a safe and productive in-person meeting. In order to ensure the safety of all attendees, the email clearly stated that unvaccinated people would not be permitted into the conference and expo campus without a current, negative SARS-CoV-2 antigen test or verified proof of vaccination.
As per its latest update, AACC now requires all meeting participants to be vaccinated, and for all meeting participants to have received a negative PCR or antigen COVID-19 test within 72 hours of arriving at the convention center. Proof of COVID-19 vaccination AND proof of a negative PCR or antigen coronavirus test will be required for in-person attendees of the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo. Individuals who are unable to provide both of these things will not be permitted to enter the meeting and antibody test results will not be accepted.
Additionally, mask policies will be in place and strictly enforced. All persons within the AACC meeting campus must wear a face mask covering their nose and mouth at all times they are indoors. Moreover, detailed meeting logistics and design have been laid down to prevent crowding and disperse crowding at the event, and additional measures may be taken if required. Signage will be used to encourage social distancing, plexiglass separations will be placed at points of sale, and educational session times will be staggered to reduce the number of attendees in common areas.
“Our plans to hold a safe and productive in-person meeting in Atlanta have not changed,” wrote Dr. Stephen Master. “The meeting is on, and it will be safe.”
“I encourage you to check out the conference program if you haven’t already. And I look forward to seeing many of you in Atlanta next month,” he added.
Related Links:
American Association for Clinical Chemistry
Latest AACC 2021 News
- Study Showing Differing COVID-19 Antibody Profiles Among Vaccinated and Naturally Infected Individuals Presented at AACC 2021
- Study Reveals Varying Antibody Responses and Adverse Reactions Among Recipients of Different COVID-19 Vaccines
- Novel Study on Performance of Coronavirus Tests in Children Presented at 2021 AACC Annual Scientific Meeting
- New Rapid Test That Identifies Deteriorating COVID-19 Patients with Greater Accuracy than Existing Tests Presented at AACC 2021
- New Blood Test for Occupational Stress Identifies Healthcare Professionals Burned out from COVID-19 Pandemic
- New Non-Invasive Saliva Test for Early and Accurate Detection of Prostate Cancer Presented at AACC 2021
- New Non-Invasive Blood Test for Colon Cancer Presented at 2021 AACC Annual Scientific Meeting
- Study Establishing Accurate Reference Intervals for Pregnant Patients Presented at AACC 2021
- New Test that Measures Antibodies in Girls Who Have Received HPV Vaccine Presented at AACC 2021
- Novel Insights on COVID-19 Vaccines and Virus Evolution, AI in the Clinic, and Miniaturization of Diagnostic Platforms Explored at AACC 2021
- Seegene Unveils New STARlet-AIOS All-in-One Solution for All Molecular Testing at AACC 2021
- Group K Diagnostics Demonstrates KromaHealth Kit that Enables Lab-Quality Results at Point-of-Care
- NGeneBio Showcases NGS-Based Oncology/Genetic Diseases Kits and NGenePlex nCoV qRT-PCR Kit Against COVID-19
- Visby Medical Presents New Portable PCR COVID-19 Test Kit at 2021 AACC Annual Scientific Meeting & Clinical Lab Expo
- Fluxergy Introduces First-of-Its-Kind Multi-Modal Laboratory Platform That Diagnoses COVID-19 On-Site in 60 Minutes
- Mammoth Biosciences Presents AACC 2021 Disruptive Technology Award Finalist CRISPR-Based Detection Platform
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read moreMolecular Diagnostics
view channel
Blood-Based Biomarker Panel Outperforms Existing Liver Disease Tests
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver dysfunction, affecting about one in three adults. Diagnosis often occurs late and still relies in part... Read more
HPV Assay Gains Expanded CE Mark for Self-Collected Vaginal Samples
Cervical cancer is the fourth most common cancer in women and is largely preventable through vaccination and regular screening. However, even where organized screening programs exist, participation varies... Read more
Fully Automated Test Advances Hepatitis D Diagnosis and Monitoring
Hepatitis D virus infection can accelerate progression to cirrhosis and liver cancer, making timely diagnosis and longitudinal monitoring essential. Because hepatitis D depends on co-infection or superinfection... Read more
Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
Cell-Free Assay Detects Functional IgE for Food Allergy Diagnosis
Accurately distinguishing sensitization from clinically relevant food allergy remains a challenge for laboratories, as routine blood tests detect allergen-specific immunoglobulin E (IgE) but not its capacity... Read more
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read moreMicrobiology
view channel
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
Mapping the spatial distribution of disease-relevant molecules within tissue remains a diagnostic challenge, particularly before alterations are visible by conventional microscopy. In Fabry disease, a... Read more
AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
Lung cancer is the leading cause of cancer-related death, and many patients require rapid genotyping to guide targeted therapy selection. Current workflows often rely on molecular tests that are costly,... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition
Leica Biosystems, an operating company of Danaher, has entered into a definitive agreement to acquire privately held StatLab Medical Products from Linden Capital Partners and Audax Private Equity.... Read more










